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Abstract
There is a growing interest in research aimed at better understanding the disease status or predicting the prognosis of patients with
simple blood tests associated with systemic inﬂammation. The neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR),
platelet-lymphocyte ratio (PLR), and mean platelet volume (MPV) can be used as factors to determine the prognosis of patients in
various clinical situations. However, reference values for these attributes based on large, healthy populations have yet to be
determined.
From January 2014 to December 2016, data from routine blood analyses were collected from healthy patients in the checkup
center of a tertiary hospital in Seoul, South Korea. Retrospective data review was then performed on an electronic medical record
system. Data were treated anonymously as only age, sex, bodymass index, medical history including cancer diagnosis, medications,
and smoking status were considered. After the initial screen, we had a collection of 12,160 samples from patients without any
medical history, including cancer treatment. This patient pool consisted of 6268 (51.5%, median age 47 years) and 5892 (48.5%,
median age 46 years) male and female patients, respectively. The mean NLR across all ages was 1.65 (0.79), and the values for men
and women were 1.63 (0.76) and 1.66 (0.82), respectively. The mean LMR, PLR, and MPV were 5.31 (1.68), 132.40 (43.68), and
10.02 (0.79), respectively. This study provides preliminary reference data on LMR, PLR, and MPV from different age and sex groups
in South Korea. The results suggest that different cutoff values should be applied to the various patient populations.
Abbreviations: BMI = body mass index, IRB = Institutional Review Board, LMR = lymphocyte-monocyte ratio, MPV = mean
platelet volume, NLR = neutrophil-lymphocyte ratio, PLR = platelet-lymphocyte ratio, SD = standard deviation.
Keywords: lymphocyte-monocyte ratio, mean platelet volume, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio1. Introduction
With the correlation between inﬂammatory status and disease or
cancer prognosis, there is a growing interest in research aimed at
better understanding the disease status or predicting the
prognosis of patients with simple blood tests. The neutrophil-
lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR),
platelet-lymphocyte ratio (PLR), and mean platelet volume
(MPV) can be used as factors to determine the prognosis of
patients in various clinical situations.Editor: Wael Alkhiary.
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1The NLR, which can be measured in simple blood tests, is
easily obtained, and determined in a cost-effective manner. As a
marker of systemic inﬂammation, NLR has been shown to be
effective in predicting the prognosis of cancer treatments,
coronary interventions, coronary artery bypass grafting, and
Alzheimer disease.[1–6] Likewise, the LMR, PLR, and MPV have
been reported to measure the degree of systemic inﬂammation
and indicate prognosis in critically ill patients during postopera-
tive and intensive care.[7–9]
As a result, thesemarkers can be easily applied in clinical practice.
There is a possibility of identifying a disease or predicting health
status using the NLR or other markers of the general population in
healthy patients or those who are undiagnosed with disease.
However, many differences exist in these markers depending on
race, sex, and age. Currently, there is no standardized level of
measurement demonstrating the signiﬁcance of a value when it is
higher than that of the average healthy patient. Therefore, the
present study was designed to evaluate the sex- and age-speciﬁc
reference values of NLR, LMR, PLR, and MPV according from
blood samples taken from a healthy patient population.2. Methods
This retrospective study was approved by the Institutional
Review Board (IRB) of Gangnam Severance Hospital, Yonsei
University College of Medicine, Seoul, South Korea (protocol
number: 3-2016-0281; date of approval: December 2016).
Because this was a retrospective study of data from precollected
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Lee et al. Medicine (2018) 97:26 Medicineblood samples treated anonymously, the IRB gave a waiver for
individual consent.
From January 2014 to December 2016, data from routine
blood analyses were collected from healthy patients in the
checkup center of a tertiary hospital in Seoul, South Korea.
Hematologic measurements were conducted by the hospital
clinical laboratory department, which performed internal quality
controls at every 8 hours using calibrator XN-CAL and XN-CAL
PT regularly, with XN-9000 automated hematology analyzers
(Sysmex Corporation, Kobe, Japan). Between-assay coefﬁcient of
variation (%) of hematologic parameters were the 1.28 of white
blood cell count, 1.99 of neutrophil %, 2.47 of lymphocyte %,
and 3.93 of monocyte %. External quality assurance of this
clinical laboratory was conducted by a government authorized
organization, the Korean association of quality assurance for
clinical laboratories.
Retrospective data review was then performed on an electronic
medical record system. Data were treated anonymously as only
age, sex, body mass index (BMI), medical history including
cancer diagnosis, and smoking status were considered.
2.1. Statistical analysis
NLR was calculated by dividing neutrophil count by lymphocyte
count. Same calculation method applied for other ratios which
are LMR and PLR. After conﬁrmation of a normal distribution,
parameters were compared using independent samples test and
intergroup comparison was performed using analysis of variance
test. Relations in between data were analyzed with Pearson
correlation analysis.
For the statistical analysis, SPSS 23.0 (SPSS Inc, Chicago, IL)
software was used. P values <.05 were considered statistically
signiﬁcant.m
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r3. Results
From January 2014 to December 2016, 20,122 patients visited
the health checkup center of a tertiary hospital in Seoul, South
Korea and received a routine blood analysis that included
assessment of differential counts of white blood cells. After the
initial data screen, we had a collection of 12,160 samples from
patients without any medical history, including cancer treatment.
The patient pool consisted of 6268 (51.5%, median age 47 years)
and 5892 (48.5%, median age 46 years) males and females,
respectively (Table 1). The number of patients according to BMI
was also analyzed.
NLR, LMR, PLR, and MPV were analyzed based on sex and
age (Table 2). Because all the data ﬁt a normal distribution, we setTable 1
Basic sample characteristics (n=12160).
Variables Categories Subject tested
Sex Male 6268 (51.5%)
Female 5892 (48.5%)
Age, y Male 46.64 (10.79)
Female 45.99 (11.14)
BMI, kg/m2 <18.5 633 (5.2%)
18.5–24.9 8044 (66.15%)
25–29.9 2931 (24.10%)
>30 441 (3.63%)
Values are mean (SD), or number (proportion).
BMI=body mass index. T
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Lee et al. Medicine (2018) 97:26 www.md-journal.comthe reference values as the mean±1.96 standard deviation. Our
analysis showed that the mean NLR across all ages was 1.65
(0.79), and the values for men and women were 1.63 (0.76) and
1.66 (0.82), respectively. The mean LMR, PLR, and MPV were
5.31 (1.68), 132.40 (43.68), and 10.02 (0.79), respectively. These
data demonstrate that all markers differed signiﬁcantly between
men and women (P< .05). Except for the NLR, the values were
higher in women than in men. Figure 1 shows the trends and
changes of each marker with age and sex.
4. Discussion
The present study provides the ﬁrst report of reference values for
NLR, LMR, PLR, and MPV according to sex and age of more
than 10,000 patients from a single racial group. A few studies
have been published showing the reference or normal values for
these factors; however, these studies were conducted using from a
small cohort of patients with different races. To the best of our
knowledge, this is the ﬁrst study to compare multiple markers
such as NLR, LMR, PLR, and MPV by age or sex from a large,
healthy population of a single race.
The NLR has been described as a predictor of mortality in
patients with acute coronary syndrome and many different types
of cancer. This marker has also been reported to predict the
prognosis of critically ill patients in intensive care.[1–6] Generally,
a higher NLR is correlated with high mortality and poor
prognosis. Many retrospective, prospective studies have sug-Figure 1. NLR (A), LMR (B), PLR (C), and MPV (D) in men and women in different
NLR=neutrophil-lymphocyte ratio, PLR=platelet-lymphocyte ratio. Data shown ar
age group.
3gested “high risk” cutoff levels of pretreatment NLR from
Kaplan-Meier curves and multivariate Cox-regression analysis.
These studies often, however, do not consider the disease
category, age, and race of patients, which are important
attributes for applying this data to clinical situations. For
example, the NLR cutoff values for prognosis from different
studies varies from 2.5 to 5, and studies from western countries
suggest a higher cutoff value than Asian or African ones.[10–13] A
study of the average value and racial difference in the United
States reported that the NLRwas higher than 2 in all races except
non-Hispanic black patients.[14] The results of our study showed
that the NLR in the Asian population was generally lower than
other races, which is consistent with previous studies. The mean
NLR across all ages in men and women was 1.63 (0.76) and 1.66
(0.82), respectively.
The NLR was also different between sexes at the same age
(Fig. 1A). Several studies have showed that hematopoiesis
changes at different estrogen levels during menopause.[15] Sex
hormones, which are represented by estrogen and progesterone,
increase neutrophil recruitment from the bone marrow, as well as
delay apoptosis. Thus, it was not surprising to observe a
signiﬁcant decrease in neutrophil count in women older than 40
years in our study. A decrease in neutrophil count in menopause
women with relatively unchanged lymphocyte count results in a
decrease in NLR. Consequently, the NLR in women is higher in
age groups of<50 years than men, whereas in age groups of>51
years, it is the reverse.age groups. LMR= lymphocyte-monocyte ratio, MPV=mean platelet volume,
e mean (standard deviations) of mean in men and women, respectively, in each
Lee et al. Medicine (2018) 97:26 MedicineAlthough NLR is the most representative marker under
investigation, many studies have focused on other baseline
hematological markers which suggest a systemic inﬂammatory
response. Tumor-associated monocytes, another main regulator
of cancer inﬂammation, also play a major role in the systemic
inﬂammation response to tumors. Thus, LMR has been suggested
to be an important factor for predicting prognosis in patients with
hematologic malignancies and tumors, such as lung cancer or
colon cancer.[16,17]
In this study, the mean LMR was 5.31 (1.68). The effects of
menopause on hematopoiesis were also seen in the LMR
(Fig. 1B). This baseline for this marker is also thought to vary
according to race, age, and sex; however, normal or reference
values from a healthy population have yet to be reported. In
previous studies, patients with preoperative LMR under 2.57 or
2.83 were considered a “high risk” group with various solid
tumors and lymphomas.[17,18] These cutoff values are included in
the reference value of LMR in this study. In order to apply LMR
cutoff values based on a normal healthy population, further
studies of baseline differences by race, age, and sex should be
performed.
Platelets secrete and express a large number of substances that
are important mediators of coagulation, thrombosis, and
inﬂammation. The platelet count and volume determined by
hematopoiesis are affected by the systemic inﬂammatory state.
MPV, as a determinant of platelet function, is a newly emerging
risk factor for atherothrombosis and may become a potentially
useful prognostic biomarker in cardiovascular patients. PLR
based on platelet count variation was also studied as a prognostic
inﬂammatory marker associated with multiple cancers. There
have yet to be any studies showing the reference values of MPV
and PLR. Our study demonstrates that the mean reference value
for PLR and MPV are 132.40 (46.794–218.006) and 10.020
(8.471–11.570), respectively. These results may provide prelimi-
nary data for further studies.
This study was conducted to establish the preliminary
reference values of NLR, LMR, PLR, and MPV in a healthy
general public. To approximate the normal values of NLR and
other markers of healthy cohort, we used the data from health
check-up in tertiary hospital and excluded patients with any
medical history and current medications. Considering the
drinking and smoking cessation for health check-up for 3 to 7
days, it is thought to be the maximum effort to ensure the
consistency of the physical status of the patients.
The present study had some limitations. First, NLR, LMR,
PMR, and MPV are known to be associated with the
inﬂammatory response. Thus, we excluded patients with any
medical history because of the potential for anti-inﬂammatory
effects stemming from some medications. We also excluded data
from patients with any cancer history because of the possibilities
of chemotherapy or radiation therapy. As a result, our data may
underestimate the degree of systemic inﬂammation in the healthy,
disease-free population. Second, we did not control the process
and timing of blood collection and analysis. Depending on the
length of time between blood collection and analysis, the
composition of blood cells could be altered or destroyed. In
particular, platelets can swell over time and cause inaccurate
MPV results.
This study provides preliminary reference data on NLR, LMR,
PMR, and MPV from different age and sex groups in South
Korea. The data suggest that different cutoff values should be set
according to race and age. Despite being inexpensive and easy,
the application of hematologic markers in clinical practice can be4challenging because of a lack of standardization and evidence. In
order to determine the level or cutoff at which disease progression
can be predicted, the evaluation of normal or reference values is
required. Therefore, this study may be helpful for the establish-
ment of thresholds which predict disease progression in various
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